Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
3
×
deals
3
×
life sciences
3
×
national blog main
national top stories
san francisco blog main
3
×
san francisco top stories
amgen
cancer
cancer drugs
clinical trials
eli lilly
investing
roche
the column group
abbvie
allergan aesthetics
alzheimer's disease
astrazeneca
athira pharma
attralus
avapritinib
biontech
blueprint medicines
boehringer ingelheim
boston
boulder/denver blog main
boulder/denver top stories
chiesi farmaceutici
cholestatic liver diseases
click therapeutics
cobimetinib
covid-19
cstone pharmaceuticals
cullinan oncology
cystic fibrosis
daniel o'day
detroit blog main
What
drug
3
×
cancer
medicines
acquisitions
approval
biggest
bio
blueprint
build
buy
candidate
ceo
company’s
currently
daniel
debut
despite
dyne’s
family
fda
gilead
hardest
hit
hottest
hunters
ipo
marketing
microbiome
moves
muscle
openly
o’day
pact
pipeline
proteins
ras
reels
regulatory
research
ret
Language
unset
3
×
Current search:
drug
×
unset
×
" san francisco blog main "
×
deals
×
" life sciences "
×
" boston top stories "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer